Sales Enablement
Week ending September 6, 2026
1. What’s coming up in conversations this week
- Ozempic vs. Wegovy: Seven answers addressed whether they are “the same medicine or just different brands.” AI consistently says both contain semaglutide, but differ in approved use, formulation, and dosing. Patients may ask whether one can be substituted for the other.
- Safety and eligibility: Prescribers are likely to hear questions about thyroid C-cell tumor warnings, pancreatitis, contraindications, pregnancy/breastfeeding, and serious allergy. These remain prominent themes.
- Combination therapy: “Are there important drug interactions…especially with insulin or sulfonylureas?” appeared in seven responses. The recurring concern is additive hypoglycemia risk.
- Kidney disease: Answers repeatedly discuss use in CKD, generally distinguishing no routine renal dose adjustment from the need to monitor dehydration, GI effects, and renal function.
- Practical dosing: Starting/titration, missed doses, and what to do if pancreatitis is suspected are highly actionable questions reps may hear directly.
2. Competitive talking points
Wegovy is the clear leader in mentions (25), although down from 44 last week. AI frames Ozempic and Wegovy as sharing semaglutide while having different approved purposes and dosing approaches. Be ready for: “If they’re the same ingredient, why not use Wegovy?” Anchor the conversation in the specific patient, indication, and current prescribing information—not brand equivalence.
In the Trulicity/Mounjaro comparison (seven responses each), AI emphasizes indication-specific labeling and warns against assuming comparable outcomes. Circulating AI language includes claims that one product is “superior” or “leading.” Treat these as unverified AI-generated language; do not repeat them as established messaging. Use approved, indication-specific materials and route medical-claim questions appropriately.
3. Questions and objections to be ready for
- “Can Ozempic be used for weight loss in someone without diabetes?” Seven responses, frequently mentioning Wegovy and off-label use. Be ready to distinguish product indication from online weight-loss discussions.
- “What exactly are the boxed warnings/major warnings—and what symptoms should I watch for?” Seven responses. AI answers vary in whether they include allergy and kidney-related warnings, so provide a consistent label-based overview and direct clinical questions to Medical.
- “How should Ozempic be used with kidney disease or worsening renal function?” Seven responses, with inconsistent inclusion of hypoglycemia and contraindication details. Be ready to separate renal dosing from dehydration/monitoring considerations.
- “If I miss a dose, should I skip it or take it later?” Seven responses conflict between a 48-hour and five-day threshold. Reps should not improvise; use the current prescribing information and approved resources.
4. What’s changed since last week
This is a lower-volume week: 81 responses vs. 120, 12 questions vs. 20, and 22 inconsistency flags vs. 32. Competitor mentions also fell sharply. However, contraindication tags rose from 28 to 34, while kidney and pregnancy/lactation tags increased modestly. These are priority refresh topics, not new competitive trends.
5. Recommended actions
- Add a call-prep note on Ozempic/Wegovy distinctions and approved indications.
- Issue a clear missed-dose reference; explicitly avoid conflicting AI-derived thresholds.
- Refresh the CKD, hypoglycemia, pancreatitis, and contraindication FAQ using current approved materials.
- Flag Trulicity/Mounjaro comparisons for battlecard review, especially “superior/leading” language.
- No broad competitive reset needed; mentions are down week over week.